U.S. Markets closed

AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials

  • AstraZeneca Plc (NASDAQ: AZN) announced detailed results from the SERENA-2 Phase 2 trial of camizestrant in pretreated post-menopausal patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer.

  • The data showed that camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) at 75mg and 150mg dose levels versus Faslodex (fulvestrant) 500mg in patients previously treated with endocrine therapy.

  • In the overall population, camizestrant significantly reduced the risk of disease progression or death by 42% at a 75mg dose with a median PFS of 7.2 versus 3.7 months and 33% at a 150mg dose with median PFS of 7.7 versus 3.7 months compared to Faslodex, the current SERD standard of care.

  • Among the prespecified subgroup of patients with ESR1 mutations, camizestrant showed a 67% reduction in the risk of disease progression or death at a 75mg dose and a 45% reduction at a 150mg dose.

  • The company also announced detailed results from the CAPItello-291 Phase 3 trial of capivasertib + Faslodex (fulvestrant) combo in patients with hormone receptor (HR)-positive, HER2-low or negative, locally advanced or metastatic breast cancer.

  • Results showed capivasertib in combination with Faslodex demonstrated a 40% reduction in the risk of disease progression or death versus placebo plus Faslodex in the overall trial population.

  • Price Action: AZN shares are up 0.75% at $69.36 on the last check Thursday.

  • Photo Via Wikimedia Commons

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.